203 Infos zu Heinz Lubenau

62 Aktuelle Nachrichten

... Heinz Lubenau, Ph.D., chief operating officer and co-founder of VAXIMM. “Individualized therapy is at the cutting edge of cancer treatment today, and, with Heinz Lubenau, Ph.D., chief operating officer and co-founder of VAXIMM. “Individualized therapy is at the cutting edge of cancer treatment today, and, with ...

Heinz Lubenau, Chief Operating Officer of VAXIMM, will give a corporate presentation. The Company will also host one-on-one meetings at this event. To ... Heinz Lubenau, Chief Operating Officer of VAXIMM, will give a corporate presentation. The Company will also host one-on-one meetings at this event. To ...

... Heinz Lubenau 6 , Marco Springer 6 , Sébastien Wieckowski 7 , Klaus M Breiner 7 , Gerd Mikus 2 , Markus W Büchler 1 , Anne-Valerie Keller 6 , Ruhan Koc Heinz Lubenau 6 , Marco Springer 6 , Sébastien Wieckowski 7 , Klaus M Breiner 7 , Gerd Mikus 2 , Markus W Büchler 1 , Anne-Valerie Keller 6 , Ruhan Koc

— Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen — Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen ...

7 Profile in Sozialen Netzwerken

Sehen Sie sich das Karriere-Profil von Heinz Lubenau (Deutschland) auf LinkedIn an. LinkedIn ist das weltweit größte professionelle Netzwerk, das Fach- und ...

Heinz Lubenaus berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, das Fach- und Führungskräften wie Heinz Lubenau dabei hilft, ...

Heinz Lubenau (Vaximm GmbH). Lubenau, Heinz (Vaximm Managing Director Vaximm GmbH before BioGeneriX before Servier). Organisation, Vaximm ... Heinz Lubenau (Vaximm GmbH). Lubenau, Heinz (Vaximm Managing Director Vaximm GmbH before BioGeneriX before Servier). Organisation, Vaximm ...

Heinz Lubenau hat 9 Jobs im Profil angegeben. Sehen Sie sich auf LinkedIn das vollständige Profil an und erfahren Sie mehr über die Kontakte von Heinz Lubenau und über Jobs bei ähnlichen Unternehmen VAXIMM. Früher. VAXIMM,; BioGeneriX AG,; Servier Forschung und Pharmaentwicklung GmbH. Ausbildung. Ontbrekend: sap

4 Hobbys & Interessen

— Dr. Heinz Lubenau, Chief Operating Officer und Mitbegründer von VAXIMM, sagte: „Wir freuen uns, diese Allianz mit NEC einzugehen und die ... › news › home

Recent bibliographic sampling of Heinz Lubenau patents listed/published in the public domain by the USPTO (USPTO Patent Application #,Title):

— Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM) All actual figures have been sourced and analyzed from publicly available ... › neo...

1 Firmen-Beteiligungen

Vaximm AG in Basel ✓ aktiv ✓ Gegründet ✓ Management: Prof. Dr. Dr. Tomas Dezsö Szucs u.a ✓ Letzte Änderung: ✓

3 Business-Profile

Dr. / Chief Operating Officer / Mannheim / diabetes, Drug development and project management expertise, transition to clinical first-in-human trials, cardiology, national and European Scientific Advice experience, and hypertension., biosimilar development background

Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through ... Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through ...

BIOGENERIX AG, Neustadt, DE

2 Firmen-Mitarbeiter

Management Team VAXIMM has a strong management team of experienced leaders with outstanding scientific knowledge and medical development expertise. Supervisory

Dr. Heinz Lubenau hat VAXIMM im Jahr mitgegründet Im Jahr begann er bei Servier und übernahm die Funktion des Clinical Research Manager und ... › ueber-uns

2 Persönliche Webseiten

... Heinz Lubenau. Co-Founder & CEO, VAXIMM. Helen Chen. Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner , L.E.K. Consulting Heinz Lubenau. Co-Founder & CEO, VAXIMM. Helen Chen. Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner , L.E.K. Consulting.

VAXIMM AG Technologiepark Basel . CH Basel Schweiz. Verwaltungsratspräsident: Dr. Thomas Hecht. VAXIMM GmbH. MAFINEX-Technologiezentrum Mannheim Deutschland. Geschäftsführer: Dr. Heinz Lubenau. . HRB

2 Besitz

... Heinz LUBENAU. The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic Heinz LUBENAU. The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic ...

This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections....

2 Bücher zum Namen

von K Breiner · — Klaus Breiner is the Executive Chairman, and Dr. Heinz Lubenau, General Manager of VAXIMMVAXIMM was formed in as a joint venture of BB Biotech Ventures ... von K Breiner · — Klaus Breiner is the Executive Chairman, and Dr. Heinz Lubenau, General Manager of VAXIMMVAXIMM was formed in as a joint venture of BB Biotech Ventures ...

... Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer, Tobias Friedrich, Heinz Lubenau, Marco Springer, Klaus M. Breiner, Gerd Mikus ...

5 Dokumente

von S Wieckowski · — ... Heinz Lubenau. Heinz Lubenau. 2Vaximm GmbH, Mannheim, Germany;. Search for other works by this author on: This Site · PubMed · Google Scholar. von S Wieckowski · — ... Heinz Lubenau. Heinz Lubenau. 2Vaximm GmbH, Mannheim, Germany;. Search for other works by this author on: This Site · PubMed · Google Scholar.

... Heinz Lubenau, Michael Platten. Organizations. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany Heinz Lubenau, Michael Platten. Organizations. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany ...

... Heinz Lubenau, Marco Springer, Klaus M. Breiner, Nicolas Hohmann, Walter E. Haefeli, Gerd Mikus, Juergen Weitz, Alexis Ulrich, Markus W. Büchler, Philip Heinz Lubenau, Marco Springer, Klaus M. Breiner, Nicolas Hohmann, Walter E. Haefeli, Gerd Mikus, Juergen Weitz, Alexis Ulrich, Markus W. Büchler, Philip ...

8 Wissenschaftliche Publikationen

Inventors: Walter Hinderer, Heinz Lubenau. BIS-MMF DERIVATIVES. Publication number: Abstract: The present invention relates to novel compounds ... Inventors: Walter Hinderer, Heinz Lubenau. BIS-MMF DERIVATIVES. Publication number: Abstract: The present invention relates to novel compounds ...

von H Lubenau · — Heinz Lubenau, PhD,1* Rolf Pokorny, MD,2* Luis Lopez-Lazaro, MD,2* Peter Bias, MD,3* Bruce Wallin, MD,4* Walter Hinderer, PhD,1* Anne-Katrin Maly,1* Michael ... von H Lubenau · — Heinz Lubenau, PhD,1* Rolf Pokorny, MD,2* Luis Lopez-Lazaro, MD,2* Peter Bias, MD,3* Bruce Wallin, MD,4* Walter Hinderer, PhD,1* Anne-Katrin Maly,1* Michael ...

von AG Niethammer · · Zitiert von: 68 — Authors and Affiliations. Vaximm, Mannheim, Germany. Andreas G Niethammer, Heinz Lubenau & Marco Springer. Clinical Pharmacology and ... von AG Niethammer · · Zitiert von: 68 — Authors and Affiliations. Vaximm, Mannheim, Germany. Andreas G Niethammer, Heinz Lubenau & Marco Springer. Clinical Pharmacology and ...

Inventors: Marco Springer, Heinz Lubenau. NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY. Publication number: Abstract: The present ... Inventors: Marco Springer, Heinz Lubenau. NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY. Publication number: Abstract: The present ...

6 Allgemeine Veröffentlichungen

von H Lubenau · · Zitiert von: 74 — Heinz Lubenau,1 Peter Bias,2 Anne-Katrin Maly,1 Karl Ernst Siegler3 and Kai Mehltretter4. 1 BioGeneriX AG, Mannheim, Germany. 2 Merckle GmbH, Ulm, Germany von H Lubenau · · Zitiert von: 74 — Heinz Lubenau,1 Peter Bias,2 Anne-Katrin Maly,1 Karl Ernst Siegler3 and Kai Mehltretter4. 1 BioGeneriX AG, Mannheim, Germany. 2 Merckle GmbH, Ulm, Germany

— Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager ... Heinz Lubenau, General Manager. Taylor & Francis. September — Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager ... Heinz Lubenau, General Manager. Taylor & Francis. September

— Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC. OncoImmunity is the ideal company to take VAXIMM's novel neoantigen — Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC. OncoImmunity is the ideal company to take VAXIMM's novel neoantigen ...

... contains supplementary material, which is available to authorized users. Andreas G Niethammer, Heinz Lubenau contributed equally to this work.

4 Meinungen & Artikel

— Hartmut Ehrlich, CEO, ABIVAX; Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH; Holger Reithinger, General Partner, Forbion Capital — Hartmut Ehrlich, CEO, ABIVAX; Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH; Holger Reithinger, General Partner, Forbion Capital ...

— Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC's novel AI technology will enable not only the — Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC's novel AI technology will enable not only the ...

22 VAXIMM AG HEINZ LUBENAU COO Heinz Lubenau co-founded VAXIMM in and currently serves as Chief Operating Officer leading all the development activities of the Company. Prior to thishe was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, ...

89 Webfunde aus dem Netz

— Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen — Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen ...

Heinz Lubenau. Top Post. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA · Experimental Cancer Drug May Slow Inflammation Linked to ... Heinz Lubenau. Top Post. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA · Experimental Cancer Drug May Slow Inflammation Linked to ...

Heinz Lubenau. HL. Heinz Lubenau. Chief Drug Development Officer at NEC OncoImmunity AS. Show contact. Heinz Lubenau has an extensive work experience in the ... Heinz Lubenau. HL. Heinz Lubenau. Chief Drug Development Officer at NEC OncoImmunity AS. Show contact. Heinz Lubenau has an extensive work experience in the ...

Get Heinz Lubenau information like Emails, Phone Number, Company, Colleagues, Competitors, Peers, Interests, Skills, Seniority. Get Heinz Lubenau information like Emails, Phone Number, Company, Colleagues, Competitors, Peers, Interests, Skills, Seniority.

... Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Kaidre Bendjama, Director, Personalized Vaccine, Transgene, Katherine Schultheis, Head of Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Kaidre Bendjama, Director, Personalized Vaccine, Transgene, Katherine Schultheis, Head of ...

Heinz-Lubenau.jpeg. Heinz Lubenau, PhD – Chief Executive Officer & Co-Founder VAXIMM ; Katka-Franke.jpeg. Katka Franke, PharmD PhD – Oncology Drug Development ... Heinz-Lubenau.jpeg. Heinz Lubenau, PhD – Chief Executive Officer & Co-Founder VAXIMM ; Katka-Franke.jpeg. Katka Franke, PharmD PhD – Oncology Drug Development ...

von AG Niethammer · · Zitiert von: 68 — doi: Authors. Andreas G Niethammer , Heinz Lubenau, ... von AG Niethammer · · Zitiert von: 68 — doi: Authors. Andreas G Niethammer , Heinz Lubenau, ...

, Paul-Ehrlich-Institut, Langen, Germany. Heinz Lubenau, VAXIMM GmbH, Mannheim, Germany. Marjan de Mey, Ghent University, Belgium. Anne S. Meyer, University of ... , Paul-Ehrlich-Institut, Langen, Germany. Heinz Lubenau, VAXIMM GmbH, Mannheim, Germany. Marjan de Mey, Ghent University, Belgium. Anne S. Meyer, University of ...

von S Wieckowski · · Zitiert von: 1 — ... Heinz Lubenau Show FewerAuthors Info & Affiliations. Publication: Journal of Clinical Oncology. Volume 36, Number 5_suppl · https://doi.org JCO von S Wieckowski · · Zitiert von: 1 — ... Heinz Lubenau Show FewerAuthors Info & Affiliations. Publication: Journal of Clinical Oncology. Volume 36, Number 5_suppl · https://doi.org JCO

· Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM. Key companies covered in the report. · Bavarian Nordic. · Genocea Biosciences. · Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM. Key companies covered in the report. · Bavarian Nordic. · Genocea Biosciences.

von K Breiner · — Hum Vaccin Immunother Nov;9(11): doi: hv Epub Sep 16. Authors. Klaus Breiner , Heinz Lubenau. Affiliation. von K Breiner · — Hum Vaccin Immunother Nov;9(11): doi: hv Epub Sep 16. Authors. Klaus Breiner , Heinz Lubenau. Affiliation.

HEINZ LUBENAU et. al. NEC ONCOIMMUNITYCOMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 · Summary Related Patents View Abstract: The present ... HEINZ LUBENAU et. al. NEC ONCOIMMUNITYCOMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 · Summary Related Patents View Abstract: The present ...

Heinz Lubenau. Chief Drug Development Officer · Saverio Niccolini's profile picture. Saverio Niccolini. Chief Operating Officer. View in org chart. Timeline. Heinz Lubenau. Chief Drug Development Officer · Saverio Niccolini's profile picture. Saverio Niccolini. Chief Operating Officer. View in org chart. Timeline.

... Date 2008; Founders Andreas Niethammer, Heinz Lubenau, Klaus Breiner; Operating Status Active; Last Funding Type Grant; Legal Name Vaximm AG. Company Type Date 2008; Founders Andreas Niethammer, Heinz Lubenau, Klaus Breiner; Operating Status Active; Last Funding Type Grant; Legal Name Vaximm AG. Company Type ...

— Contact: VAXIMM AG Dr. Heinz Lubenau Tel.: + Media Inquiries: MC Services AG. Katja Arnold, Laurie — Contact: VAXIMM AG Dr. Heinz Lubenau Tel.: + Media Inquiries: MC Services AG. Katja Arnold, Laurie ...

VAXIMM's Chief Executive Officer & Co-Founder is Heinz Lubenau. Other executives include Thomas D. Szucs, Chairman; Marc Mansour, Chief Scientific Officer ... VAXIMM's Chief Executive Officer & Co-Founder is Heinz Lubenau. Other executives include Thomas D. Szucs, Chairman; Marc Mansour, Chief Scientific Officer ...

Heinz Lubenau. Dr. Heinz Lubenau, General Manager and Head of Development at VAXIMM GmbH. Link to Healthcaree Industry Baden-Württemberg ... Heinz Lubenau. Dr. Heinz Lubenau, General Manager and Head of Development at VAXIMM GmbH. Link to Healthcaree Industry Baden-Württemberg ...

Mitglied des Verwaltungsrats: Heinz Lubenau · Prokura: Heinz Lubenau · Präsident des Verwaltungsrats: Klaus Breiner · Prokura: Klaus Breiner ... Mitglied des Verwaltungsrats: Heinz Lubenau · Prokura: Heinz Lubenau · Präsident des Verwaltungsrats: Klaus Breiner · Prokura: Klaus Breiner ...

... Heinz Lubenau, PhD, Auro Del Giglio, MD. Journal of Thoracic Oncology. Volume 4 Issue 6 Pages (June 2009). DOI: JTO.0b013e3181a Copyright Heinz Lubenau, PhD, Auro Del Giglio, MD. Journal of Thoracic Oncology. Volume 4 Issue 6 Pages (June 2009). DOI: JTO.0b013e3181a Copyright ...

von H Lubenau · · Zitiert von: 74 — Gale Academic OneFile includes Pharmacokinetic and pharmacodynamic profile of new bios by Heinz Lubenau, Peter Bias, Anne-Katrin . Click to explore. von H Lubenau · · Zitiert von: 74 — Gale Academic OneFile includes Pharmacokinetic and pharmacodynamic profile of new bios by Heinz Lubenau, Peter Bias, Anne-Katrin . Click to explore.